LEGN | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-3.20%

1 Month

6.89%

3 Months

-36.54%

6 Months

-50.53%

1 Year

-48.56%

2 Year

-71.96%

Key data

Stock price

$17.85

P/E Ratio

0.00

DAY RANGE

$17.58 - $18.22

EPS

N/A

52 WEEK RANGE

$16.24 - $45.30

52 WEEK CHANGE

-$47.78

MARKET CAP

10.492 B

YIELD

N/A

SHARES OUTSTANDING

182.305 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-08-2025

BETA

0.64

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,365,622

AVERAGE 30 VOLUME

$2,326,594

Company detail

CEO: Ying Huang
Region: US
Website: legendbiotech.com
Employees: 1,070
IPO year: 2020

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Legend Biotech Corporation engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for gastric cancer and T cell lymphoma.

LEGN - Legend Biotech Corp